Alkem Laboratories Ltd. announced its financial results for the second quarter ended September 30, 2026 (Q2FY27), reporting a consolidated revenue growth of 13.8% year-on-year, reaching ₹45,520 million. EBITDA saw a growth of 11.3% to ₹10,252 million, however, Profit After Tax (PAT) declined by 11.7% to ₹6,753 million, primarily due to a higher effective tax rate. The company also highlighted strong performance in its domestic business and international markets.
Alkem Laboratories Reports Strong Revenue Growth in Q2FY27
Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the second quarter ended September 30, 2026 (Q2FY27). The company reported a robust 13.8% year-on-year revenue growth, with Total Revenue from Operations reaching ₹45,520 million.
Key Financial Highlights
- Total Revenue from Operations stood at ₹45,520 million, a 13.8% YoY growth.
- India sales contributed ₹30,275 million, showing a 9.5% YoY growth.
- International sales grew by 22.3% to ₹14,540 million.
- EBITDA increased by 11.3% YoY to ₹10,252 million, with an EBITDA margin of 22.5%.
- Profit After Tax (PAT) saw a de-growth of 11.7% YoY to ₹6,753 million, attributed mainly to a higher effective tax rate.
- Net cash stood at ₹49,054 million as of September 30, 2026.
Domestic Business Performance
The domestic business registered a growth of 9.5% YoY, with sales at ₹30,275 million. The company noted that its overall performance was in line with the Indian Pharmaceutical Market (IPM) growth of 13.8%. Alkem outperformed IPM in eight key therapies, including Anti-Infectives, Pain/Analgesics, and Anti-Diabetic segments. Branded business grew by 12.1%.
International Business Performance
International markets showed significant growth, with Non-US sales surging 58% YoY to ₹6,710 million, contributing 15% to total sales. US sales grew 2.4% YoY to ₹7,830 million. The integration of Occlutech in MedTech also contributed to the sales mix from Q2FY27 onwards.
Operational and Regulatory Updates
The company provided updates on its facilities, including a successful inspection by the US FDA at its Mandva API plant with zero observations. Regulatory updates also mentioned the Daman (India) formulations facility receiving OAI with response submitted and remediation in progress.
Key Financial Metrics Overview
For Q2 FY27, Total Revenue from Operations was ₹45,520 million (up 13.8% YoY). EBITDA was ₹10,252 million (up 11.3% YoY) with a margin of 22.5%. Reported PAT was ₹6,753 million (down 11.7% YoY).
Source: BSE
